Modality
Fusion Protein
MOA
Anti-Aβ
Target
EGFR
Pathway
STING
PAH
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
Jun 2021
→ Sep 2031
Phase 2Current
NCT05936591
2,080 pts·PAH
2021-06→2030-06·Completed
NCT07715723
1,481 pts·PAH
2023-05→2031-09·Recruiting
3,561 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-06-284.2y awayPh3 Readout· PAH
2031-09-045.4y awayPh3 Readout· PAH
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Complet…
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-06-28 · 4.2y away
PAH
Ph3 Readout
2031-09-04 · 5.4y away
PAH
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05936591 | Phase 2/3 | PAH | Completed | 2080 | ORR |
| NCT07715723 | Phase 2/3 | PAH | Recruiting | 1481 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| RCU-2903 | Arcus Bio | NDA/BLA | EGFR | |
| Capicilimab | Structure Ther | Phase 1 | EGFR |